EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Clinical trials for EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) explained in plain language.
Never miss a new study
Get alerted when new EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) trials appear
Sign up with your email to follow new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for aggressive lung cancer: drug cocktail trial launches
Disease control Recruiting nowThis study tests if adding extra drugs to a standard treatment can better control extensive-stage small cell lung cancer. About 180 adults will receive ivonescimab plus chemotherapy, with some also getting AK117 or cadonilimab. The goal is to shrink tumors and manage side effects…
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 16, 2026 22:37 UTC
-
New hope for aggressive lung cancer: experimental drug combo enters final testing
Disease control Recruiting nowThis study tests whether adding the experimental drug obrixtamig to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer. About 670 adults with extensive-stage disease will be randomly assigned to receive either the new combination…
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
Engineered immune cells take on tough lung cancer in early trial
Disease control Recruiting nowThis study tests a new treatment called DJI136, which uses a patient's own immune cells (T-cells) that are modified in a lab to target a protein called DLL3 found on cancer cells. It is for adults with extensive-stage small cell lung cancer that has worsened after standard treatm…
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
Promising drug cocktail aims to stall aggressive lung cancer
Disease control Recruiting nowThis study tests whether combining two FDA-approved drugs—sacituzumab govitecan and an immunotherapy (atezolizumab or durvalumab)—can control tumor growth in adults with extensive-stage small cell lung cancer. Participants receive the drug combo every 21 days for up to 2 years, w…
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Bindu R Potugari • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
Targeted hope: new drug trial for aggressive lung cancer
Disease control Recruiting nowThis study tests a drug called teniposide in 15 people with advanced small cell lung cancer that has a specific gene change (c-Myc). Participants must have already tried standard treatment without success. The goal is to see if the drug can shrink tumors and control the disease, …
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New hope for advanced lung cancer? drug combo plus radiation tested in 36 patients
Disease control Recruiting nowThis study tests a new treatment for people with extensive stage small cell lung cancer, a fast-growing cancer that has spread. The treatment combines an immunotherapy drug (tislelizumab) with chemotherapy, followed by chest radiation and then maintenance therapy. The goal is to …
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Chongqing University Cancer Hospital • Aim: Disease control
Last updated Jun 10, 2026 13:28 UTC
-
New triple therapy aims to extend life in aggressive lung cancer
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy and radiation can help people with extensive small cell lung cancer live longer without their cancer growing. About 56 adults who have not had prior treatment for this advanced cancer wil…
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Anhui Provincial Cancer Hospital • Aim: Disease control
Last updated Jun 09, 2026 12:10 UTC
-
New hope for aggressive lung cancer: experimental drug faces standard care in major trial
Disease control Recruiting nowThis study tests whether the drug sacituzumab govitecan helps people with advanced small cell lung cancer live longer compared to usual treatments. About 695 adults whose cancer worsened after one round of chemotherapy will be randomly assigned to receive the study drug or standa…
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 09, 2026 12:08 UTC
-
New triple therapy targets stubborn lung cancer in early trial
Disease control Recruiting nowThis early-phase study is for people with extensive-stage small-cell lung cancer whose disease persists, returns, or progresses after initial chemotherapy. Researchers are testing whether adding an experimental drug (iadademstat) to standard radiation and immunotherapy (atezolizu…
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE1 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 09, 2026 12:06 UTC